Esphera SynBio Announces New Project to Advance Next Generation mRNA Vaccine Development

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

Esphera SynBio, a pre-clinical stage synthetic biology company, announced a new project aimed at advancing next-generation mRNA vaccines. Using its proprietary technology, Esphera SynBio causes the production of modified nanomedicines within patients upon delivery of LNP/mRNA vaccines. These in situ produced nanomedicines can have precise targeting capabilities and tailored immunostimulatory payloads, unlocking new possibilities in vaccine innovation. This project is supported by the CQDM Quantum Leap program.

Esphera SynBio is an OBIO® member and presented at the OBIO® Investment Summit.

Arsheen Kaur
Previous

Lab2Market Awarded Government of Canada Grant to Propel Innovation & Commercialization in Canada
Next

Enhanced Medical Nutrition Raises Series A Funding to Revolutionize Nutrition for Surgery